0
0
The Overlooked Crisis: Older Australians and Overdose Deaths
A new national report published in August 2025 has revealed a dramatic shift in drug overdose patterns in Australia, highlighting a steep rise in overdose deaths among adults aged 50 and older. While unintentional overdose deaths have decreased by about one-third among people under 30 since 2001, fatalities among Australians aged 50-59 have tripled, and those among 60-69 year-olds have nearly doubled in the same period. This emerging health crisis calls for urgent attention from healthcare professionals, policymakers, and the public alike.
Key Findings: Who is Most at Risk?
Recent data from Australia’s Annual Overdose Report and supporting agencies detail a shifting demographic profile:
-
Opioids remain the leading cause of drug-induced deaths, responsible for both illicit (heroin) and prescribed (oxycodone, codeine) overdose fatalities.
-
Between 2019 and 2023, one-third of all heroin deaths were among 40-49 year-olds (704 deaths), while the 50-59 year-old cohort accounted for 20% (451 deaths).
-
For pharmaceutical opioids, individuals aged 50 and over represented more than 38% of fatal overdoses. The 40-49 group had 619 deaths, followed by 508 in the 50-59 group and 330 among those 60+.
-
Other substances, including benzodiazepines and amphetamines, have shown increased involvement in overdose deaths among older adults, although opioids remain the primary risk factor.
Compounding these statistics, in 2021, there were 1,933 alcohol and drug-induced deaths among older adults in Australia, with men experiencing rates more than twice as high as women. The overdose death rate among those aged 50-59 rose from 18.7 to 27.1 per 100,000 people over two decades.
Why Are Older Australians at Greater Risk?
Physiological Vulnerabilities
As individuals age, they develop more chronic health conditions and are often prescribed multiple medications. Reduced liver and kidney function slows the metabolism of many drugs, allowing substances—even at previously tolerated doses—to accumulate to dangerous levels. Opioids are particularly hazardous, as they can depress breathing and heart rate. Risk of fatal interactions increases dramatically when opioids are combined with alcohol, sedatives, or other medications, a situation not uncommon among older populations.
The Ageing Cohort Effect
Experts point to the “ageing cohort theory” as a powerful driver of these statistics. Many middle-aged Australians dying from overdose began using drugs decades ago, especially in the 1980s and 1990s, and have carried their substance use into later life. National estimates suggest the median age of people who inject drugs has climbed from 28 to over 43, and the age of first injection has shifted from late teens to the late 20s or 30s. This means that rather than a new generation adopting drug use, a long-exposed group is bearing the brunt of today’s overdose crisis.
Stigma and Access Barriers
Older adults using illicit or non-prescribed pharmaceuticals often face significant stigma, which can deter them from seeking help. Health professionals may also be less likely to discuss substance use with older patients, leaving risks unaddressed. Additionally, accessibility issues—like daily treatment requirements and insufficient treatment centers—further hinder overdose prevention efforts.
Expert Perspectives
Dr. Jake Dizard, director of research at the Penington Institute, emphasized the preventable nature of these deaths and compared the situation to road safety: “These deaths are preventable. If you look at things like the road toll, there’s Vision Zero and a national road safety strategy. We don’t have that for drugs”.
Another addiction medicine specialist, not involved in the specific studies, explained: “Age-related changes in metabolism and increased comorbidity load mean that the same dose of a drug can have vastly different effects as people get older. Polypharmacy and lack of regular medication review further increase the risk of catastrophic interactions.”
Public Health Implications
The shifting burden of overdose deaths toward older populations necessitates a comprehensive rethinking of Australia’s drug harm reduction strategies. Addressing this crisis involves:
-
Expanding access to opioid agonist therapies (such as methadone and buprenorphine), which have been shown to halve overdose risk, yet remain underutilized due to stigma, high costs, and rigid treatment models.
-
Increased availability and distribution of naloxone, a medication that can quickly reverse opioid overdoses. In Australia, it is now available for free and without a prescription at pharmacies and harm reduction services.
-
Routine substance use screening for all age groups, not just younger people, during healthcare visits.
-
Targeted education for older adults and their caregivers about safe medication practices and the risks of drug interactions, particularly for those using prescription opioids or benzodiazepines.
Limitations and Conflicting Perspectives
It’s important to acknowledge data limitations. Not all overdoses are reported or accurately classified, potentially leading to underestimation of the problem. The focus on opioid-related deaths may also overlook growing issues with alcohol, benzodiazepines, and amphetamines in this demographic. Some experts caution against attributing the surge solely to prescription drugs, arguing that underlying social and mental health determinants, such as isolation and lack of support for chronic pain and addiction, also demand attention.
What Can Readers Do?
Older adults, their loved ones, and healthcare teams should regularly review medications, seek support for substance-related issues without fear of stigma, and ensure access to harm reduction resources. Policymakers and practitioners must recognize the changing face of Australia’s overdose crisis and deliver age-appropriate, evidence-based interventions.
Medical Disclaimer:
This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
